In June 2024 a room in Paris filled up with some of the most cited names in Alzheimer's research: neuropathologists from Tokyo and Sao Paulo, biomarker specialists from Lund, epidemiologists from Toulouse, clinicians from Rochester and London. Two other people were in that room. One was living with dementia. One was a family caregiver. According to the paper that came out of the meeting, they did not give testimony and then leave; they took part throughout. The authors write that "the lived experience perspective was central to these discussions." It is a small sentence, and it carries a heavy load, because everything about the format says otherwise: the meeting was a think tank of experts, and the two voices from the other side of the desk were outnumbered by an order of magnitude.
The record of that meeting was published on 15 June 2026 in Alzheimer's & Dementia, open access, as Volume 22, Issue 6, article e71536, by Philippe Amouyel, Sandrine Andrieu, Angela Bradshaw and colleagues, with Heather M. Snyder of the Alzheimer's Association as corresponding author. It is the second gathering of the Global Alzheimer's Leadership Series, a joint initiative of the Fondation Alzheimer in France and the Alzheimer's Association in the United States, and it was followed by a featured research session at the 2024 Alzheimer's Association International Conference that widened the exchange. Families should know exactly what they are reading when they open it. This is a meeting report and an expert perspective. It is not a survey, not a trial, not a study. Nobody was sampled, nothing was counted, no percentage of patients was compared with any percentage of doctors. The word "perspectives" in the title is doing honest work.
And yet the gap the piece is reaching for is visible in its own summary. The authors note that differing perspectives on the definition of Alzheimer's exist, and that where those perspectives converge is on the underlying biological substrate of the disease and how it translates into the clinic: biomarkers, early treatment, the recognition of co-pathologies and of atypical clinical presentations. That is a real and hard-won consensus. It is also, read from a kitchen table rather than a conference table, a consensus about vocabulary that no family chose. The question a person brings to a memory clinic is rarely whether their amyloid status is confirmed. It is whether they can still drive, whether their partner is exaggerating, whether the forgetting has a name and what that name will cost them at work. The paper's own conclusion, that clinical diagnosis at this point in time is appropriate and useful for medical decision-making only within certain limits, is a boundary drawn in clinical language about a moment that patients experience as anything but bounded.
What the authors put on the provider side of the ledger is worth reading slowly, because it is close to an admission. They highlight shared decision-making, clear and transparent communication, and the need for real-world data to support patients holistically through what they go through. They call shared decision-making a critical component of managing treatment pathways, and they add the condition that usually goes missing: that those discussions have to be made meaningful to patients and caregivers. Naming something as critical is, in the quiet grammar of consensus documents, a way of saying it is not yet standard. The closing call is for continued collaboration among clinicians, researchers, policymakers and patient advocacy groups, and for clear communication, patient-centred care, equitable access and ongoing real-world evidence. None of that is new language. What is new is who was sitting in the room when it was written down.
The stakes behind the politeness are concrete. The paper is written against a landscape in which, as the authors note, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended granting a marketing authorisation for lecanemab in mild cognitive impairment or mild dementia due to Alzheimer's disease, restricted to people carrying one copy or no copies of the APOE e4 allele, and in which blood-based biomarkers have changed how early the conversation can start. That means the clinic appointment now contains a genetic result, an eligibility rule, a monitoring schedule and a risk discussion, all of which are conducted in the language of the people who wrote this paper. Nothing here tells any reader what to take or whether any treatment is right for them; that conversation belongs to a person and their own clinician. But the more technical the decision becomes, the more the phrase "shared decision-making" has to earn its keep, and the fewer minutes there are in a twenty-minute appointment for the question the patient actually came in with.
There is one more thing the publication record shows. The meeting took place in June 2024. The manuscript reached the journal on 11 February 2025, came back revised on 10 April 2026, was accepted on 26 April 2026 and appeared on 15 June 2026. Two years from the room to the page. Somewhere in that interval, the person living with dementia who sat through those discussions in Paris went on living with it, in real time, at the speed at which this condition actually moves.